DDInter1086 DDInter1628
An alkylating agent of value against both hematologic malignancies and solid tumors.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Lomustine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Lomustine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lomustine {u} (Compound) causes {v} (Side Effect) Contusion
Contusion {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Lomustine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lomustine {u} (Compound) binds {v} (Gene) STMN4
STMN4 {u} (Gene) covaries with {v} (Gene) KIAA0907
KIAA0907 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Lomustine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phenobarbital
Phenobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lomustine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) and {u} (Diease) associated with {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vinblastine
Vinblastine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Lomustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Lomustine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Lomustine (Compound) causes Contusion (Side Effect) and Contusion (Side Effect) is caused by Ruxolitinib (Compound)
Lomustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Lomustine (Compound) binds STMN4 (Gene) and STMN4 (Gene) covaries with KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Ruxolitinib (Compound)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Ruxolitinib (Compound)
Lomustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Lomustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates RET (Gene) and hematologic cancer (Diease) associated with RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)